PCOS Diagnostic Market Size, Share & Trends Analysis Report By Type (Pelvic Exam, Blood Test, Transvaginal Ultrasound), By End User (Hospitals & Clinics, Fertility Clinics, Others), By Region, And Segment Forecasts, 2024-2031

PCOS Diagnostic Market Size is predicted to witness a 5.0% CAGR during the forecast period for 2025-2034.

PCOS (polycystic ovarian syndrome) is a hormonal condition affecting many women of reproductive age. PCOS is characterized by irregular or prolonged menstrual cycles as well as high levels of male hormones. Although there is no cure for PCOS, various medications are used to regulate the menstrual cycle and manage the condition's symptoms. It is also caused by high levels of androgens, low-grade inflammation, ovarian cysts, too much insulin, and hereditary abnormalities. The polycystic ovarian syndrome diagnostic industry is growing due to increased PCOS prevalence, patient awareness, and increased usage of combination therapy. Furthermore, simple access to PCOS treatments, rising demand for PCOS drugs, and technical developments in PCOS screening all have an impact on market growth. 

However, the COVID-19 outbreak had a huge influence on the healthcare industry. The polycystic ovarian syndrome (PCOS) therapy market is not immune to the pandemic's consequences, which impacted various surgical procedures, including laparoscopic ovarian drilling. To combat the COVID-19 pandemic, various governments-imposed lockdown and social distancing restrictions, which resulted in the suspension of multiple operations, supply chain disruptions, stifling business growth, and the shutdown of new developments, which had a negative impact on the market. 

Recent Developments:

• In January 2022, a biotechnology company Celmatix Inc. focused on ovarian biology, announced the achievement of a third milestone in its five-year, multi-target cooperation with Evotec. Evotec and Bayer AG have reached a significant milestone by moving a PCOS therapy program centered on a unique Celmatix-identified therapeutic target into hit identification. 

Competitive Landscape:

Some of PCOS diagnostic market players are:

• Siemens Healthineers AG
• GE Healthcare
• Mindray Medical International Limited
• Esaote S.p.A
• Telemed Medical Systems
• Shantou Institute of Ultrasonic Instruments Co., Ltd. (SIUI)
• BK Medical
• Alpinion Medical Systems
• Mindray ZONARE Medical Systems
• Xianfeng Ultrasound Medical. 

Market Segmentation:

The PCOS diagnostic market is segmented on the basis of test type and end user. Based on test type, the market is segmented as blood tests, pelvic exams, and ultrasound (transvaginal). The end-user segment includes hospitals & clinics, fertility clinics, and others.

Based On Test Type, The Ultrasound (Transvaginal) Segment Is Accounted As A Major Contributor To The PCOS Diagnostic Market

The ultrasound (transvaginal) category is expected to hold a major share of the global PCOS diagnostic market in 2022. This can be attributable to the fertility issues that women suffer as a result of this illness, as well as the fact that women's responses to drugs often wane over time. Furthermore, this process is inexpensive and simple to carry out, propelling the segment's rise worldwide.

The Hospitals & Clinics Segment Is To Witness Growth At A Rapid Rate

The hospitals & clinics segment is projected to increase in the global PCOS due to the rising frequency of PCOS and associated operations that are performed more frequently in hospital settings. Hospitals are the first choice for diagnosing and treating PCOS. Because no single test can specifically diagnose polycystic ovarian syndrome (PCOS), clinicians must first diagnose PCOS patients. The doctor or patient's health care provider will most likely begin by discussing their symptoms, medications, and any other medical conditions they may be experiencing. The doctor may also ask about menstrual cycles and weight swings. Search for signs of acne, insulin resistance, and excessive hair growth during a physical exam.

The North American PCOS Diagnostic Market Holds A Significant Revenue Share In The Region

The North American PCOS Diagnostic Market is expected to register the highest market share in revenue in the near future. The rising prevalence of obesity and overweight is increasing the number of people suffering from PCOS, which is one of the primary reasons driving market expansion in North America. Furthermore, increased knowledge of the benefits of frequent checkups is contributing to an increase in the number of new cases detected in this region each year.

Moreover, Europe is expected to grow at a significant rate. These governments are working on reducing the rising prevalence of PCOS by implementing programs that assist PCOS diagnosis and treatment, as well as the necessary lifestyle changes. These programs are raising awareness about PCOS and its related concerns, such as the development of insulin resistance, obesity, and, in some circumstances, infertility.

PCOS Diagnostic Market Report Scope: